Find clinical trials for Adenocarcinoma in Rochester, MN
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Adenocarcinoma trials near Rochester, MN, USA:
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Phase 3
Rochester, Minnesota, United States and 42 other locations
(CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...
Phase 3
Rochester, Minnesota, United States and 284 other locations
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitab...
Phase 3
Rochester, Minnesota, United States and 118 other locations
Cohort 1 \[CLOSED\] Study treatment involves two segments: (1) Induction Immunotherapy segment with pembrolizumab monotherapy every 3 weeks until irR...
Phase 2
Rochester, Minnesota, United States and 1 other location
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Phase 3
Rochester, Minnesota, United States and 59 other locations
in individuals with pathologically confirmed pancreatic ductal adenocarcinoma. Following screening, using a standardized administration prot...
Phase 3
Rochester, Minnesota, United States and 14 other locations
with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma...
Phase 2, Phase 3
Rochester, Minnesota, United States and 161 other locations
in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosphorylase (MTAP) d...
Phase 2, Phase 3
Rochester, Minnesota, United States and 269 other locations
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON...
Phase 1, Phase 2
Rochester, Minnesota, United States and 31 other locations
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN1...
Phase 1, Phase 2
Rochester, Minnesota, United States and 24 other locations
Clinical trials
Research sites
Resources
Legal